Craif Expands Public Funding for MySignal to Cover All Applicants with Supplementary Budget

Craif Inc. (Location: Shinjuku-ku, Tokyo; Representative Director & CEO: Ryuichi Onose; hereinafter "Craif"), a bio-AI startup, announced that its public subsidy project for the urine cancer risk test "MySignal," implemented in Misato Town, Shimane Prefecture, has seen the town compile a supplementary budget to expand the target framework. This expansion is in response to "MySignal" becoming an opportunity to reach individuals who have had limited contact with existing specific health checkups and cancer screenings. The initial target of 100 people for public subsidies has been expanded to cover all 283 applicants. This project aims to demonstrate the effectiveness of MySignal as a new entry point for health checkups and to promote its adoption by municipalities nationwide.

Project Outcomes

The introduction of public subsidies for MySignal has proven effective in promoting screening behavior among those who had not previously undergone specific health checkups or cancer screenings. Among the 283 applicants, an analysis of national health insurance subscribers (n=100) for whom detailed data was available revealed that approximately 8.3% (*1) of those who had not received specific health checkups for the past three years were motivated to apply and undergo screening through this project. Furthermore, applications were also received from individuals who had not undergone lung cancer, colorectal cancer, stomach cancer, or breast cancer screenings for the past three years. This demonstrates the effectiveness of reaching populations that are difficult to engage with through existing screening systems.

*1. Rate of application from 253 individuals who had not undergone specific health checkups under the National Health Insurance in FY R7.

MySignal Public Subsidy Project Overview (After Supplementary Budget)

For residents of Misato Town, Shimane Prefecture, aged 40-74, MySignal testing will be provided to those who undergo specific health checkups (including comprehensive medical checkups and workplace health checkups) in FY2026. The test can be taken at two clinics within the town, and individuals identified as high-risk based on their test results will receive comprehensive support, including additional examinations at specialized medical institutions.

Target Audience

Residents of Misato Town aged 40-74 who undergo specific health checkups (including comprehensive medical checkups and workplace health checkups) in FY2026.

Cost

Public Subsidy: Approximately \50,000 Self-Payment: \15,000 (for National Health Insurance subscribers of Misato Town)

\20,000 (for others)

Capacity

All applicants (283 people this fiscal year: 100 National Health Insurance, 173 non-National Health Insurance)

Application Period

Until May 15, 2026

Test Start Date

Mid-June 2026

Results Delivery & Additional Testing

From Mid-July 2026

Testing Facilities

Daiwa Clinic / Hatano Clinic

Additional Testing Facilities

Izumo Tokushukai Hospital, etc. (for those identified as high-risk)

Background of the Initiative

In Japan, one in two people develop cancer, and the cancer screening rate remains low internationally at around 40%. Particularly in rural areas with limited access to medical facilities, the difficulty in accessing screenings further lowers the screening rate. In Misato Town, Shimane Prefecture, challenges in accessing medical institutions and the tendency to postpone screenings due to daily busyness persist, resulting in cancer screening rates below the target value (*2). Preventing severe illness and increased medical costs due to delayed detection is an urgent issue.

Craif is collaborating with Misato Town on this project with the aim of realizing a society where each resident can live a long and healthy life through early cancer detection and treatment. MySignal, which can be tested simply by collecting urine, is a convenient test for those who have difficulty accessing medical institutions or are busy with their daily lives to check their cancer risk. As a direct solution to these regional challenges, Craif is partnering with Misato Town to realize the nation's first municipal public subsidy for MySignal.

*2. Average rate for targeted screening is approximately 26% (Misato Town Cancer Screening Results, 2024).

Craif's Initiatives in Collaboration with Municipalities

Craif has been promoting the social implementation of MySignal through collaborations with municipalities and medical institutions. In 2024, a prospective observational study was conducted in Iwanai Town, Hokkaido, which led to the early detection and treatment of Stage 0 lung cancer triggered by MySignal. Subsequently, Craif has also collaborated with Rishiri Town, Hokkaido, to advance initiatives aimed at improving regional cancer screening rates, accumulating a track record of collaboration with municipalities.

The introduction of public funding in Misato Town is a new social model that promotes early cancer detection led by municipalities, built upon these achievements. Craif will continue to deepen its collaborations with municipalities and medical institutions to realize a society where as many people as possible can detect cancer early.

About "MySignal Scan"

"MySignal Scan" is a test that analyzes microRNAs in urine using AI to assess the risk of 10 types of cancer, including pancreatic cancer, from Stage 1 onwards, categorized by cancer type. It is a non-invasive test that can be performed simply by collecting urine.

For details, please visit our website.

https://misignal.jp/

"MySignal Scan" is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for medical diagnosis to determine if one has cancer. Even if the risk is determined to be low, it does not guarantee the absence of cancer or that cancer will not develop in the future.

* Ovarian and breast cancer are tested for women only; prostate cancer is tested for men only.

About Craif

Craif (pronounced "Crayf") is a bio-AI startup founded in 2018, dedicated to the early detection of cancer. By integrating its proprietary analysis technology platform "NANO IP®︎ (NANO Intelligence Platform)" for high-precision detection of various biomarkers such as DNA and microRNA from bodily fluids including urine, with AI technology, the company develops innovative tests that enable ultra-early cancer detection, treatment, and recovery. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of "realizing a society where people live out their natural lifespans."

【Company Profile】

Company Name: Craif Inc.

Representative: Ryuichi Onose, Representative Director

Established: May 2018

Capital: 100 million yen (as of April 1, 2025)

Business: Research and development of next-generation tests for early detection of diseases, primarily in the cancer field, and personalized medicine; provision of the urine cancer risk test "MySignal®."

Head Office: THE PORTAL iidabashi B1F, 8-30 Shinkawa, Shinjuku-ku, Tokyo

URL: https://craif.com/